Prognostic model and treatment choices for patients with primary intracranial central nervous system lymphoma: A population-based study

被引:2
|
作者
Jiang, Qingsong [1 ]
Zhan, Guoyong [1 ]
Jiang, Wenhong [2 ]
Xu, Yafeng [3 ]
Zheng, Guofu [1 ]
Jiang, Cai [1 ]
Lin, Dongdong [4 ]
Wang, Kang [1 ]
Zhu, Huiwu [5 ,6 ]
机构
[1] KeCheng Peoples Hosp, Dept Neurosurg, Quzhou, Zhejiang, Peoples R China
[2] KeCheng Peoples Hosp, Dept Med Records Informat Technol, Quzhou, Zhejiang, Peoples R China
[3] KeCheng Peoples Hosp, Dept Nursing, Quzhou, Zhejiang, Peoples R China
[4] Zhejiang Univ, Affiliated Zhejiang Hosp, Brain Ctr, Sch Med, Hangzhou, Peoples R China
[5] KeCheng Peoples Hosp, Brain Ctr, Quzhou, Zhejiang, Peoples R China
[6] 172 Shuanggang Rd, Quzhou, Zhejiang, Peoples R China
关键词
Primary central nervous system lymphoma; SEER; Prognostic model; PRIMARY CNS LYMPHOMA; WHOLE-BRAIN RADIOTHERAPY; INTERNATIONAL EXTRANODAL LYMPHOMA; INTRACEREBRAL MALIGNANT-LYMPHOMA; HIGH-DOSE METHOTREXATE; RACIAL-DIFFERENCES; RADIATION-THERAPY; RITUXIMAB; SURVIVAL; CHEMOIMMUNOTHERAPY;
D O I
10.1016/j.clineuro.2023.107912
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Primary central nervous system lymphoma (PCNSL) is a non-Hodgkin lymphoma that occurs in the CNS. With the advancement of medical care, its prognosis and treatment have also undergone tremendous changes. This study aimed to construct a prognostic model and compare the effects of different treatments for intracranial PCNSL. Methods: Cases diagnosed as PCNSL between 2004 and 2015 were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Data were analyzed using Kaplan-Meier method and Cox regression analysis. Nomogram was built and validated using the R program. Results: A total of 2861 PCNSL patients were included in the analysis. Age, year of diagnosis, surgery and chemotherapy were independent predictors for both overall survival (OS) and cancer-specific survival (CSS). A nomogram was established to predict 3-, 5- and 10-year OS and CSS for patients. Receiver operating characteristic (ROC) curves and decision curve analysis (DCA) showed the nomogram had good predictive performance and clinical application value. We also revealed that gross total resection had significantly better OS and CSS than biopsy alone (P < 0.001). Patients who received only chemotherapy had the best prognosis and did not benefit from additional radiotherapy. Conclusion: We developed a nomogram to predict patient survival rates based on independent predictors. It is an effective tool to help clinicians make survival predictions. Our results showed that patients can benefit from gross total resection of tumor, if it is feasible, and chemotherapy. The role of radiotherapy remained to be further assessed.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] POPULATION-BASED INCIDENCE AND SURVIVAL FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN KOREA, 1999-2009
    Yoo, Heon
    Jung, Kyu-Won
    Lee, Seung Hoon
    Shin, Sang-Hoon
    Ha, Johyun
    Won, Young-Joo
    [J]. NEURO-ONCOLOGY, 2013, 15 : 36 - 36
  • [32] Patients with Primary Central Nervous System Lymphoma Not Eligible for Clinical Trials: Prognostic Factors, Treatment and Outcome
    Seidel, Sabine
    Margold, Michelle
    Kowalski, Thomas
    Baraniskin, Alexander
    Schroers, Roland
    Korfel, Agnieszka
    Thiel, Eckhard
    Weller, Michael
    Martus, Peter
    Schlegel, Uwe
    [J]. CANCERS, 2021, 13 (12)
  • [33] A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma
    Jang, Ji Eun
    Kim, Yu Ri
    Kim, Soo-Jeong
    Cho, Hyunsoo
    Chung, Haerim
    Lee, Jung Yeon
    Park, Hyunsung
    Kim, Yundeok
    Cheong, June-Won
    Min, Yoo Hong
    Kim, Jin Seok
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 57 : 127 - 135
  • [34] Safety and efficacy of primary central nervous system lymphoma treatment in elderly population
    Gaviani, Paola
    Simonetti, G.
    Innocenti, A.
    Lamperti, E.
    Botturi, A.
    Silvani, A.
    [J]. NEUROLOGICAL SCIENCES, 2016, 37 (01) : 131 - 133
  • [35] Safety and efficacy of primary central nervous system lymphoma treatment in elderly population
    Paola Gaviani
    G. Simonetti
    A. Innocenti
    E. Lamperti
    A. Botturi
    A. Silvani
    [J]. Neurological Sciences, 2016, 37 : 131 - 133
  • [36] PRIMARY THERAPY AND SURVIVAL IN OVER 70-YEAR-OLD PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A CONTEMPORARY, NATIONWIDE, POPULATION-BASED STUDY IN THE NETHERLANDS
    van der Meulen, M.
    Bromberg, J. E. C.
    Visser, O.
    Doorduijn, J. K.
    Dinmohamed, A. G.
    [J]. NEURO-ONCOLOGY, 2019, 21 : 21 - 21
  • [37] Challenges in the treatment of elderly patients with primary central nervous system lymphoma
    Roth, Patrick
    Khe Hoang-Xuan
    [J]. CURRENT OPINION IN NEUROLOGY, 2014, 27 (06) : 697 - 701
  • [38] Changing Incidence and Survival of Primary Central Nervous System Lymphoma in Australia: A 33-Year National Population-Based Study
    Farrall, Alexandra L.
    Smith, Justine R.
    [J]. CANCERS, 2021, 13 (03) : 1 - 15
  • [39] Population-Based Study of the Outcomes of Primary Central Nervous System Lymphoma (PCNSL) In the Era of Autologous Stem Cell Transplantation (ASCT)
    Owen, Carolyn J.
    Daly, Andrew
    Chua, Neil
    Stewart, Douglas A.
    [J]. BLOOD, 2010, 116 (21) : 577 - 578
  • [40] A population-based study of familial central nervous system hemangioblastomas
    Hemminki, K
    Li, XJ
    Collins, VP
    [J]. NEUROEPIDEMIOLOGY, 2001, 20 (04) : 257 - 261